Grifols Stock News

BARCELONA (Reuters) – Spanish pharmaceutical company Grifols said on Monday its 2021 net profit fell 70% to 183 million euros ($204.70 million) as the COVID-19 pandemic continued to disrupt supplies of the blood plasma it uses to make medicines.

Grifols (GIKLY) is collaborating with Endpoint Health to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis.Under the agreement, Grifols will contribute…

BARCELONA, Spain, Feb. 24, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world''s leading producers of plasma-derived medicines, today announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing…

PALO ALTO, Calif.--(BUSINESS WIRE)--Endpoint Health, Inc., a precision-firstTM therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced that the company has entered into a global collaboration and licensing agreement with Grifols, a leading global producer of plasma-derived medicines, under which Endpoint Health will receive exclusive rights to develop and commercialize Antithrombin III (AT-III) in sepsis. Under the terms of the

Grifols S.A. (NASDAQ:GRFS) shares, rose in value on Friday, 02/18/22, with the stock price up by 1.36% to the previous days close as strong demand from buyers drove the stock to $11.20. Actively observing the price movement in the last trading, the stock closed the session at $11.05, falling within a range of $11.01 and Grifols S.A. (NASDAQ: GRFS): Aiming For A Higher Share Price Read More »

Grifols currently trades at a 30% discount to European specialty pharma. GIFLF has a successful track record of M&A and is currently trading on a 2022 P/E of 16.5.

Grifols: Short-Term Turbulence But Long-Term Upside

Their dividends will be trickling into your account quarter after quarter.

There could be a downside to the consensus revenue and margins of Grifols <> (GIKLY) (GIFLF), JPMorgan analyst James D Gordon warned, issuing the firm’s earnings preview for…

CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022

CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Alla

The "Global Blood Transfusion Devices Market, By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By Blood Component (Whole Blood, Plasma, RBC, Others), By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The global blood transfusion devices market is expected to grow at a CAGR of around 6% during the forecast period. Companies Mentioned Fresenius Kabi AG Grifols SA Terumo Corporation B Braun Melsungen AG Becton, Dickinson, and Company Immucor Inc Haemonetics Corporation Kaneka Corporation Macopharma SA Tenko International Group Corp The global blood transfusion devices market is driven by upsurge in count of surgical procedures being carried out across the globe. Moreover, developments in terms of technology is expected to positively impact the growth of the market during the forecast period. Also, rise in number of blood related disorders is further expected to bolster the growth of market over the next few years.

Grifols, S.A. (NASDAQ:GRFS)s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $10.86, but opened at $10.41. Grifols shares last traded at $10.39, with a volume of 5,349 shares traded. A number of research firms recently commented on GRFS. Citigroup raised Grifols from a neutral rating to []